Cancer Metabolism: Molecular Targeting and Implications for Therapy

Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors valida...

Full description

Saved in:
Bibliographic Details
Superior document:Frontiers Research Topics
:
Year of Publication:2017
Language:English
Series:Frontiers Research Topics
Physical Description:1 electronic resource (114 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993543894104498
ctrlnum (CKB)4100000002484755
(oapen)https://directory.doabooks.org/handle/20.500.12854/42642
(EXLCZ)994100000002484755
collection bib_alma
record_format marc
spelling Shanmugasundaram Ganapathy-Kanniappan auth
Cancer Metabolism: Molecular Targeting and Implications for Therapy
Cancer Metabolism
Frontiers Media SA 2017
1 electronic resource (114 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Frontiers Research Topics
Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors validated as potential therapeutics in preclinical models. Yet, majority of anticancer principles or therapeutics show limited success in the clinical translation. Thus, the need for the development of an effective therapeutic strategy persists. “Altered energy metabolism” in cancer is one of the earliest known biochemical phenotypes which dates back to the early 20th century. The German scientist, Otto Warburg and his team (Warburg, Wind, Negelein 1926; Warburg, Wind, Negelein 1927) provided the first evidence that the glucose metabolism of cancer cells diverge from normal cells. This phenomenal discovery on deregulated glucose metabolism or cellular bioenergetics is frequently witnessed in majority of solid malignancies. Currently, the altered glucose metabolism is used in the clinical diagnosis of cancer through positron emission tomography (PET) imaging. Thus, the “deregulated bioenergetics” is a clinically relevant metabolic signature of cancer cells, hence recognized as one of the hallmarks of cancer (Hanahan and Weinberg 2011). Accumulating data unequivocally demonstrate that, besides cellular bioenergetics, cancer metabolism facilitates several cancer-related processes including metastasis, therapeutic resistance and so on. Recent reports also demonstrate the oncogenic regulation of glucose metabolism (e.g. glycolysis) indicating a functional link between neoplastic growth and cancer metabolism. Thus, cancer metabolism, which is already exploited in cancer diagnosis, remains an attractive target for therapeutic intervention as well. The Frontiers in Oncology Research Topic “Cancer Metabolism: Molecular Targeting and Implications for Therapy” emphases on recent advances in our understanding of metabolic reprogramming in cancer, and the recognition of key molecules for therapeutic targeting. Besides, the topic also deliberates the implications of metabolic targeting beyond the energy metabolism of cancer. The research topic integrates a series of reviews, mini-reviews and original research articles to share current perspectives on cancer metabolism, and to stimulate an open forum to discuss potential challenges and future directions of research necessary to develop effective anticancer strategies.
English
Tumor microenvironment
metastasis
glycolysis
immunotherapy
epigenetic regulation
metabolic reprogramming
Warburg effect
2-88945-322-7
language English
format eBook
author Shanmugasundaram Ganapathy-Kanniappan
spellingShingle Shanmugasundaram Ganapathy-Kanniappan
Cancer Metabolism: Molecular Targeting and Implications for Therapy
Frontiers Research Topics
author_facet Shanmugasundaram Ganapathy-Kanniappan
author_variant s g k sgk
author_sort Shanmugasundaram Ganapathy-Kanniappan
title Cancer Metabolism: Molecular Targeting and Implications for Therapy
title_full Cancer Metabolism: Molecular Targeting and Implications for Therapy
title_fullStr Cancer Metabolism: Molecular Targeting and Implications for Therapy
title_full_unstemmed Cancer Metabolism: Molecular Targeting and Implications for Therapy
title_auth Cancer Metabolism: Molecular Targeting and Implications for Therapy
title_alt Cancer Metabolism
title_new Cancer Metabolism: Molecular Targeting and Implications for Therapy
title_sort cancer metabolism: molecular targeting and implications for therapy
series Frontiers Research Topics
series2 Frontiers Research Topics
publisher Frontiers Media SA
publishDate 2017
physical 1 electronic resource (114 p.)
isbn 2-88945-322-7
illustrated Not Illustrated
work_keys_str_mv AT shanmugasundaramganapathykanniappan cancermetabolismmoleculartargetingandimplicationsfortherapy
AT shanmugasundaramganapathykanniappan cancermetabolism
status_str n
ids_txt_mv (CKB)4100000002484755
(oapen)https://directory.doabooks.org/handle/20.500.12854/42642
(EXLCZ)994100000002484755
carrierType_str_mv cr
hierarchy_parent_title Frontiers Research Topics
is_hierarchy_title Cancer Metabolism: Molecular Targeting and Implications for Therapy
container_title Frontiers Research Topics
_version_ 1759307578098057217
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03653nam-a2200373z--4500</leader><controlfield tag="001">993543894104498</controlfield><controlfield tag="005">20230221133615.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| eneng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000002484755</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/42642</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000002484755</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shanmugasundaram Ganapathy-Kanniappan</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer Metabolism: Molecular Targeting and Implications for Therapy</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Cancer Metabolism</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (114 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors validated as potential therapeutics in preclinical models. Yet, majority of anticancer principles or therapeutics show limited success in the clinical translation. Thus, the need for the development of an effective therapeutic strategy persists. “Altered energy metabolism” in cancer is one of the earliest known biochemical phenotypes which dates back to the early 20th century. The German scientist, Otto Warburg and his team (Warburg, Wind, Negelein 1926; Warburg, Wind, Negelein 1927) provided the first evidence that the glucose metabolism of cancer cells diverge from normal cells. This phenomenal discovery on deregulated glucose metabolism or cellular bioenergetics is frequently witnessed in majority of solid malignancies. Currently, the altered glucose metabolism is used in the clinical diagnosis of cancer through positron emission tomography (PET) imaging. Thus, the “deregulated bioenergetics” is a clinically relevant metabolic signature of cancer cells, hence recognized as one of the hallmarks of cancer (Hanahan and Weinberg 2011). Accumulating data unequivocally demonstrate that, besides cellular bioenergetics, cancer metabolism facilitates several cancer-related processes including metastasis, therapeutic resistance and so on. Recent reports also demonstrate the oncogenic regulation of glucose metabolism (e.g. glycolysis) indicating a functional link between neoplastic growth and cancer metabolism. Thus, cancer metabolism, which is already exploited in cancer diagnosis, remains an attractive target for therapeutic intervention as well. The Frontiers in Oncology Research Topic “Cancer Metabolism: Molecular Targeting and Implications for Therapy” emphases on recent advances in our understanding of metabolic reprogramming in cancer, and the recognition of key molecules for therapeutic targeting. Besides, the topic also deliberates the implications of metabolic targeting beyond the energy metabolism of cancer. The research topic integrates a series of reviews, mini-reviews and original research articles to share current perspectives on cancer metabolism, and to stimulate an open forum to discuss potential challenges and future directions of research necessary to develop effective anticancer strategies.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer Metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycolysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenetic regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolic reprogramming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Warburg effect</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-322-7</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-03 01:52:09 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2018-03-10 17:16:05 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337440820004498&amp;Force_direct=true</subfield><subfield code="Z">5337440820004498</subfield><subfield code="8">5337440820004498</subfield></datafield></record></collection>